Stock listing
NASDAQ:OKUR OnKure Therapeutics, Inc. Stock
Home listing (NASDAQ) of OnKure Therapeutics, Inc.
Follow OnKure Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:OKUR
$2.70 USD -0.12 (-4.3%)
Close on Nov 20, 2026
- Day range
- $2.68 – $2.81 USDNov 20, 2026
- Volume
- 195,211 sharesNov 20, 2026
- Market cap
- $109.4M USDAt the close on Nov 20, 2026 · price × 40.50M shares outstanding
- 52-week range
- $2.01 – $5.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $911,397 USDMedian day 240,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OKUR · Home | $2.70 USD | -0.12 (-4.3%) | 195,211 | $2.75 | $2.81 | $2.682 | $2.82 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OKUR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.70 | -0.12 | -4.3% | $2.75 | $2.81 | $2.682 | 195,211 | |
| $2.82 | +0.24 | +9.3% | $2.59 | $2.84 | $2.575 | 172,685 | |
| $2.58 | -0.17 | -6.2% | $2.60 | $2.81 | $2.50 | 228,165 | |
| $2.75 | +0.12 | +4.6% | $2.55 | $2.805 | $2.50 | 682,256 | |
| $2.63 | -0.38 | -12.6% | $3.03 | $3.08 | $2.60 | 891,350 | |
| $3.01 | -0.35 | -10.4% | $3.33 | $3.33 | $2.935 | 286,825 | |
| $3.36 | -0.025 | -0.7% | $3.40 | $3.59 | $3.345 | 205,829 | |
| $3.385 | +0.195 | +6.1% | $3.15 | $3.42 | $2.99 | 281,838 | |
| $3.19 | +0.325 | +11.3% | $2.88 | $3.21 | $2.76 | 814,191 | |
| $2.865 | +0.34 | +13.5% | $2.47 | $2.88 | $2.31 | 555,817 | |
| $2.525 | -0.065 | -2.5% | $2.54 | $2.57 | $2.315 | 325,164 | |
| $2.59 | +0.09 | +3.6% | $2.53 | $2.63 | $2.51 | 876,952 | |
| $2.50 | -0.09 | -3.5% | $2.60 | $2.60 | $2.44 | 219,375 | |
| $2.59 | -0.03 | -1.1% | $2.64 | $2.72 | $2.48 | 500,840 | |
| $2.62 | 0.00 | 0.0% | $2.61 | $2.67 | $2.53 | 306,762 | |
| $2.62 | -0.01 | -0.4% | $2.63 | $2.665 | $2.44 | 427,588 | |
| $2.63 | +0.035 | +1.3% | $2.56 | $2.661 | $2.46 | 282,588 | |
| $2.595 | +0.12 | +4.8% | $2.49 | $2.72 | $2.475 | 320,237 | |
| $2.475 | -0.045 | -1.8% | $2.53 | $2.625 | $2.38 | 258,090 | |
| $2.52 | -0.06 | -2.3% | $2.62 | $2.62 | $2.48 | 240,900 | |
| $2.58 | +0.28 | +12.2% | $2.30 | $2.59 | $2.28 | 243,800 | |
| $2.30 | -0.06 | -2.5% | $2.37 | $2.40 | $2.25 | 232,800 | |
| $2.36 | +0.11 | +4.9% | $2.25 | $2.475 | $2.25 | 235,100 | |
| $2.25 | +0.15 | +7.1% | $2.10 | $2.26 | $2.02 | 501,500 | |
| $2.10 | -0.03 | -1.4% | $2.14 | $2.14 | $2.01 | 386,000 | |
| $2.13 | -0.12 | -5.3% | $2.26 | $2.28 | $2.09 | 349,900 | |
| $2.25 | -0.095 | -4.1% | $2.29 | $2.38 | $2.21 | 381,200 | |
| $2.345 | -0.075 | -3.1% | $2.40 | $2.40 | $2.31 | 232,600 | |
| $2.42 | +0.01 | +0.4% | $2.41 | $2.47 | $2.40 | 146,400 | |
| $2.41 | +0.11 | +4.8% | $2.29 | $2.42 | $2.23 | 609,200 | |
| $2.30 | -0.05 | -2.1% | $2.34 | $2.456 | $2.13 | 519,600 | |
| $2.35 | -0.11 | -4.5% | $2.41 | $2.46 | $2.30 | 260,700 | |
| $2.46 | -0.17 | -6.5% | $2.65 | $2.65 | $2.41 | 327,500 | |
| $2.63 | +0.07 | +2.7% | $2.56 | $2.67 | $2.42 | 626,200 | |
| $2.56 | +0.02 | +0.8% | $2.57 | $2.61 | $2.46 | 526,900 | |
| $2.54 | -0.185 | -6.8% | $2.72 | $2.825 | $2.50 | 2,082,200 | |
| $2.725 | +0.125 | +4.8% | $2.63 | $2.79 | $2.50 | 831,400 | |
| $2.60 | -0.16 | -5.8% | $2.78 | $2.80 | $2.47 | 339,800 | |
| $2.76 | -0.14 | -4.8% | $2.87 | $2.879 | $2.60 | 442,200 | |
| $2.90 | -0.03 | -1.0% | $2.93 | $3.00 | $2.86 | 91,400 | |
| $2.93 | -0.01 | -0.3% | $2.96 | $3.05 | $2.88 | 149,700 | |
| $2.94 | -0.16 | -5.2% | $3.09 | $3.24 | $2.90 | 149,700 | |
| $3.10 | +0.04 | +1.3% | $3.06 | $3.11 | $2.91 | 200,800 | |
| $3.06 | +0.11 | +3.7% | $2.95 | $3.10 | $2.92 | 166,700 | |
| $2.95 | -0.01 | -0.3% | $2.96 | $3.08 | $2.91 | 223,100 | |
| $2.96 | +0.08 | +2.8% | $2.94 | $3.02 | $2.82 | 181,000 | |
| $2.88 | -0.05 | -1.7% | $2.93 | $3.005 | $2.84 | 83,900 | |
| $2.93 | -0.07 | -2.3% | $2.98 | $2.98 | $2.815 | 171,100 | |
| $3.00 | -0.10 | -3.2% | $3.11 | $3.14 | $2.978 | 105,200 | |
| $3.10 | -0.17 | -5.2% | $3.31 | $3.33 | $2.98 | 253,600 | |
| $3.27 | -0.11 | -3.3% | $3.36 | $3.42 | $3.24 | 168,500 | |
| $3.38 | -0.02 | -0.6% | $3.38 | $3.49 | $3.319 | 80,100 | |
| $3.40 | -0.18 | -5.0% | $3.55 | $3.90 | $3.34 | 115,000 | |
| $3.58 | +0.02 | +0.6% | $3.53 | $3.62 | $3.508 | 165,500 | |
| $3.56 | +0.02 | +0.6% | $3.56 | $3.62 | $3.52 | 132,200 | |
| $3.54 | -0.02 | -0.6% | $3.54 | $3.665 | $3.41 | 127,400 | |
| $3.56 | -0.07 | -1.9% | $3.62 | $3.70 | $3.494 | 193,300 | |
| $3.63 | -0.16 | -4.2% | $3.80 | $3.90 | $3.54 | 100,500 | |
| $3.79 | -0.04 | -1.0% | $3.83 | $4.02 | $3.67 | 432,500 | |
| $3.83 | +0.03 | +0.8% | $3.77 | $3.86 | $3.77 | 97,700 | |
| $3.80 | -0.05 | -1.3% | $3.86 | $4.013 | $3.70 | 80,000 | |
| $3.85 | -0.04 | -1.0% | $3.91 | $4.043 | $3.79 | 116,228 | |
| $3.89 | -0.05 | -1.3% | $3.95 | $4.39 | $3.70 | 421,074 | |
| $3.94 | +0.01 | +0.3% | $3.95 | $4.073 | $3.90 | 59,900 | |
| $3.93 | -0.15 | -3.7% | $4.04 | $4.043 | $3.78 | 103,500 |
Splits
1 split · NASDAQ:OKUR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:OKUR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 18 slides
Latest news
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Nov 4, 2026
Closed $2.53 (-2.5%) on Nov 5, 2026
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Aug 31, 2026
Closed $3.63 (-4.2%) on Aug 31, 2026
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Aug 4, 2026
Closed $4.16 (+1.5%) on Aug 5, 2026
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
Jul 2, 2026
Closed $4.58 (+2.7%) on Jul 2, 2026
OnKure Therapeutics Reports First Quarter 2026 Financial Results
May 5, 2026
Closed $4.07 (-10.0%) on May 6, 2026
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
Mar 27, 2026
Closed $3.99 (-13.1%) on Mar 27, 2026
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 12, 2026
Closed $3.78 (+7.4%) on Mar 13, 2026
OnKure Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 30 in all · newest Nov 4, 2026 · oldest 2021
- Decks
- 6 decks · latest August 2026
Where OnKure Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OKUR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:OKUR | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 2.1×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$53.16M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.17
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.21M | n/a | 59,054× | n/a | 3.6× | n/a | 0.0× | n/a |
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Medigen Biotechnology Corporation · TPEX:3176 | US$111.8M | US$61.94M | n/a | 1.6× | n/a | 2.5× | −19.9% | 0.8× | n/a |
| Fate Therapeutics, Inc. · NASDAQ:FATE | US$111.7M | US$47.08M | n/a | 9.9× | n/a | 0.8× | n/a | 0.6× | 2.25 |
| Spruce Biosciences, Inc. · NASDAQ:SPRB | US$109.2M | US$41.00M | n/a | n/a | n/a | 1.6× | n/a | 0.3× | 1.73 |
| NIBEC Co., Ltd. · KRX:138610 | US$108.0M | US$91.93M | n/a | 5.5× | 118× | 3.0× | −0.1% | 0.0× | n/a |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.67M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Median of the others | US$108.6M | US$84.44M | 9.9× | 118× | 2.1× | −19.9% | 0.2× | 1.73 |
Forecasts
5 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.61 · 2 analysts
- Revenue, year to Dec 2026
- 125K · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Nicholas A. Saccomano | President & Chief Executive Officer |
| Jason Leverone | Chief Financial Officer |
| Rogan Nunn | General Counsel and Secretary |
| Aaron Goodwin | Vice President of Pharmaceutical Sciences and Supply Chain |
| David Mareska | Vice President, Discovery Chemistry |
| James Blake | Senior Vice President of Computational Drug Discovery |
| Jim Wong | Vice President, Biological Sciences |
| Kevin S. Litwiler | Senior Vice President of DMPK and Clinical Pharmacology |
| Mark L. Boys | Senior Vice President of Discovery Chemistry |
| Qian Zhao | Vice President and Distinguished Fellow |
| Robbie Alton | Senior Vice President of Clinical Operations |
| Dylan Hartley | Chief Scientific Officer |
| Samuel Agresta | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Michael Grey | Chairman |
| Andrew Phillips | |
| Dylan Hartley | Chief Scientific Officer |
| Edward Mathers | |
| Isaac Manke | |
| Jason Leverone | Chief Financial Officer |
| Liam Ratcliffe | |
| Nicholas A. Saccomano | President & Chief Executive Officer |
| R. Michael Carruthers | |
| Rogan Nunn | General Counsel and Secretary |
| Samuel Agresta | Chief Medical Officer |
| Valerie Jansen |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −2.5% |
| Q2 2026 | Aug 4, 2026 · After close | +1.5% |
| Q1 2026 | May 5, 2026 · After close | −10.0% |
| Q4 2025 | Mar 13, 2026 | +10.8% |
| Q3 2025 | Nov 6, 2025 · After close | −7.0% |
| Q2 2025 | Aug 12, 2025 · After close | +20.0% |
| Q1 2025 | May 5, 2025 · Before open | +0.4% |
| Q4 2024 | Mar 10, 2025 · After close | −0.2% |
| Q3 2024 | Nov 7, 2024 · After close | +2.3% |
| Q2 2024 | Aug 13, 2024 | +9.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 | +5.8% |
| Q4 2023 | Mar 28, 2024 | +3.0% |
| Q3 2023 | Nov 13, 2023 | −0.9% |
| Q2 2023 | Aug 10, 2023 | −6.3% |
| Q1 2023 | May 11, 2023 | +1.8% |
| Q4 2022 | Mar 27, 2023 | −10.3% |
| Q3 2022 | Nov 8, 2022 | −3.0% |
| Q2 2022 | Aug 9, 2022 | −3.0% |
| Q1 2022 | May 11, 2022 | −11.7% |
| Q4 2021 | Mar 24, 2022 | −4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 18 slides | August 2026 |
| Technical Presentation (July 2026) | Technical | 27 slides | Jul 15, 2026 |
| Investor Presentation (June 2025) | Investor deck | 21 slides | Jun 26, 2025 |
| San Antonio Breast Cancer Symposium 2024 | Conference | 14 slides | Dec 10, 2024 |
| Investor Presentation (December 2024) | Investor deck | 21 slides | Dec 10, 2024 |
| Reneo Pharmaceuticals — Merger or Acquisition (May 2024) | Merger or acquisition | 25 slides | May 13, 2024 |
IPO
Went public as Reneo Pharmaceuticals, Inc. Priced at US$15.00 a share on Apr 8, 2021.
- Price
- US$15.00 a share
- Shares offered
- 6,250,000 shares of common stock
- Offering size
- US$93.8 million
- Underwriters' option
- Up to 937,500 more shares
- Underwriters
- Jefferies, SVB Leerink, Piper Sandler · In the order on the cover
- Shares delivered
- On or about Apr 13, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 12, 2021 |
| Filed publicly | Mar 19, 2021 |
| Amended once | Apr 5, 2021 |
| Shares registered with an exchange | Apr 6, 2021 |
| Declared effective by the SEC | Apr 8, 2021 |
| Final prospectus, with the price | Apr 9, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 9, 2021 |
| EFFECT · Notice that a registration is effective | Apr 8, 2021 |
| CERT · Exchange's certificate of listing | Apr 8, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 6, 2021 |
| CORRESP · Letter to the SEC | Apr 6, 2021 |
| CORRESP · Letter to the SEC | Apr 6, 2021 |
| S-1/A · Registration statement, amended | Apr 5, 2021 |
| CORRESP · Letter to the SEC | Mar 19, 2021 |
| S-1 · Registration statement | Mar 19, 2021 |
| UPLOAD · Letter from the SEC | Mar 12, 2021 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Feb 12, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 9, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 830.0K | 662.0K | 560.0K | 529.0K | 50.0K | 37.0K |
| Gross profit | -830.0K | -662.0K | -560.0K | -529.0K | -50.0K | -37.0K |
| Research and development | 48.3M | 43.8M | 32.1M | 37.7M | 28.2M | 15.9M |
| Selling, general and administrative | 14.7M | 10.6M | 4.82M | 3.90M | ||
| Operating income | -63.0M | -54.4M | -36.9M | -53.8M | -39.8M | -19.6M |
| Depreciation and amortization | 447.0K | 459.0K | 417.0K | 88.0K | 50.0K | 37.0K |
| EBITDA | -62.5M | -53.9M | -36.5M | -53.8M | -39.8M | -19.5M |
| Interest expense | 8.00K | 300.0K | 0 | |||
| Income before tax | -59.5M | -52.7M | -77.4M | -52.0M | -39.8M | -19.5M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -59.5M | -52.7M | -35.3M | -52.0M | -39.8M | -19.5M |
| Earnings per share, basic | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 | -9.60 |
| Earnings per share, diluted | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 | -9.60 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 59.0M | 110.8M | 29.9M | 19.9M | 124.7M | 53.6M |
| Short-term investments | 0 | 75.3M | 81.2M | 23.0M | ||
| Current assets | 60.8M | 113.0M | 33.8M | 106.4M | 153.7M | 55.0M |
| Property, plant and equipment | 618.0K | 1.02M | 1.43M | 453.0K | 212.0K | 69.0K |
| Total assets | 62.1M | 114.9M | 35.7M | 108.2M | 154.0M | 55.2M |
| Accounts payable | 1.43M | 2.97M | 3.42M | 1.89M | 2.02M | 908.0K |
| Current liabilities | 5.92M | 10.5M | 7.29M | 7.12M | 6.20M | 4.58M |
| Total debt | 549.0K | 1.08M | 674.0K | 637.0K | 92.7M | |
| Total liabilities | 5.93M | 11.1M | 7.75M | 8.21M | 6.81M | 4.62M |
| Shareholders' equity | 56.2M | 103.8M | -101.8M | -54.4M | 147.2M | -42.1M |
| Shares outstanding | 40.5M | 40.5M | 3.34M | 24.7M | 24.5M | 2.05M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -51.8M | -51.1M | -34.5M | -47.4M | -38.0M | -18.5M |
| Capital spending | -46.0K | -52.0K | -246.0K | -346.0K | -198.0K | -24.0K |
| Free cash flow | -51.9M | -51.2M | -34.8M | -47.7M | -38.2M | -18.6M |
| Cash from investing | -46.0K | 15.9M | -246.0K | -57.8M | -23.4M | 7.38M |
| Cash from financing | 163.0K | 116.1M | 53.1M | 471.0K | 132.4M | 47.3M |
| Share buybacks | -4.40M | |||||
| Change in cash | -51.7M | 80.9M | 18.3M | -104.7M | 71.0M | 36.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 10, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 4, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 30, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 24, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| 3 · Initial statement of ownership | Apr 7, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 28, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Nov 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 29, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | May 27, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | May 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 16, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 24, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 24, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 20, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 21, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Dec 9, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 7, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Oct 31, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 31, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 28, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 28, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Oct 25, 2024 | Other filings | SEC |
| S-1 · Registration statement | Oct 23, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 23, 2024 | Big-stake notice | SEC |
| D | Oct 21, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 10, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 8, 2024 | Acquisition or disposal | SEC |
| 425 | Oct 2, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2024 | Meeting outcome | SEC |
| SC 13G · Big-stake notice | Sep 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 26, 2024 | Insider trade | SEC |
| 425 | Sep 20, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Aug 27, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Aug 26, 2024 | Offer document | SEC |
This page holds 200 of 406 filings. Open Filings
Cap table
Built by 6ix from OnKure Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 40,503,094
- Fully diluted
- 40,503,094
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 40,503,094 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 40,503,094 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Mathers Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 22, 2023 · Past) | Director · Since at least Apr 8, 2021 |
| Liam Ratcliffe Other companies: Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Climb Bio, Inc. (Director · Aug 9, 2021 – Jun 26, 2024 · Past); Passage Bio, Inc. (Director · Feb 27, 2020 – May 27, 2021 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 29, 2019 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – May 17, 2018 · Past); PDS Biotechnology Corporation (Director · Jun 21, 2016 – Mar 15, 2019 · Past) | Director · Since at least Mar 27, 2026 |
| Michael Grey Other companies: Spruce Biosciences, Inc. (Executive Chairman, Director · Since at least Oct 8, 2020); Mirum Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2019); Horizon Pharma PLC (Director · Sep 29, 2011 – May 3, 2018 · Past); BioMarin Pharmaceutical Inc. (Director · Dec 14, 2006 – Mar 5, 2021 · Past); Achillion Pharmaceuticals Inc (Director · Oct 25, 2006 – Dec 18, 2009 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Dec 11, 2008 · Past); SGX Pharmaceuticals Inc (President & CEO, Director · Jan 31, 2006 – Aug 20, 2008 · Past) | Director · Since at least Apr 8, 2021 |
| Isaac Manke Other companies: Rainier Acquisition Corporation (Director · Since at least Aug 26, 2026); Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past) | Director · Since at least Oct 4, 2024 |
| R. Michael Carruthers Other companies: Elevation Oncology Inc (Director · Since at least Jun 24, 2021); Edgewise Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 25, 2021); Brickell Biotech Inc (Chief Financial Officer · Aug 31, 2019 – Mar 16, 2020 · Past); Alpine Immune Sciences Inc (Interim President / CFO · Jun 16, 2015 – Jan 12, 2017 · Past) | Director · Since at least Oct 4, 2024 |
| Andrew J. Phillips Other companies: MoonLake Immunotherapeutics (Member · Since at least Apr 5, 2022); Enliven Therapeutics, Inc. (Director · Feb 23, 2023 – Feb 6, 2025 · Past) | Director · Since at least Oct 4, 2024 |
| Ashley Hall Other companies: Structure Therapeutics, Inc. (Chief Development Officer · Since at least Sep 18, 2024); Esperion Therapeutics, Inc. (Chief Development Officer · Feb 26, 2020 – Jan 28, 2021 · Past) | Chief Development Officer · Oct 11, 2020 – Aug 28, 2023 · Past |
| Bali Muralidhar Other companies: Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020); Exicure, Inc. (Director · Jun 2, 2021 – Jun 13, 2022 · Past) | Director · Apr 8, 2021 – Jun 6, 2023 · Past |
| Niall O'Donnell Other companies: Spruce Biosciences, Inc. (Director · Oct 8, 2020 – May 25, 2023 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Nov 11, 2022 · Past) | Director · Apr 8, 2021 – Jun 6, 2023 · Past |
| Roshawn A Blunt Other companies: Kronos Bio Inc (Director · Since at least Nov 11, 2021); DMK Pharmaceuticals Corporation (Director · Aug 26, 2019 – Aug 26, 2019 · Past) | Director · Aug 2, 2022 – Jun 6, 2023 · Past |
All 34 people
| Person | Seat |
|---|---|
| Wendy S Johnson Other companies: Exagen Inc. (Director · Oct 1, 2020 – Jun 9, 2023 · Past); Armata Pharmaceuticals, Inc. (Director · Sep 8, 2015 – Sep 7, 2017 · Past) | Chief Development Officer · Apr 8, 2021 – Jul 14, 2021 · Past |
| Eric Dube Other companies: Travere Therapeutics, Inc. (Chief Executive Officer and Director · Since at least Jan 4, 2019) | Director · Apr 8, 2021 – Jun 6, 2023 · Past |
| Jason Leverone Other companies: Viridian Therapeutics, Inc. (Chief Financial Officer · Jan 18, 2021 – Jan 18, 2021 · Past) | Chief Financial Officer · Since at least Oct 4, 2024 |
| Johan Kordel Other companies: Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Feb 4, 2014 · Past) | Director · Apr 8, 2021 – Apr 8, 2021 · Past |
| Kenneth Ph D Harrison Other companies: Edgewise Therapeutics, Inc. (Director · Mar 25, 2021 – Mar 25, 2021 · Past) | Director · Apr 8, 2021 – Apr 8, 2021 · Past |
| Lon Cardon Other companies: Mirum Pharmaceuticals, Inc. (Board Member · Since at least Dec 19, 2022) | Director · Apr 8, 2021 – Apr 8, 2021 · Past |
| Samuel Agresta Other companies: Foghorn Therapeutics Inc. (Chief Medical Officer · Oct 22, 2020 – Sep 11, 2023 · Past) | Chief Medical Officer · Since at least Oct 4, 2024 |
| Stacey Denenberg Seltzer Other companies: Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past) | Director · Apr 8, 2021 – Jun 6, 2023 · Past |
| Valerie Jansen Other companies: Elevation Oncology Inc (CHIEF MEDICAL OFFICER · Jan 6, 2023 – Feb 15, 2025 · Past) | Director · Since at least Oct 4, 2024 |
| Aaron Goodwin | Vice President of Pharmaceutical Sciences and Supply Chain · Since at least Nov 4, 2026 |
| Alejandro Dorenbaum | Chief Medical Officer · Apr 8, 2021 – Dec 9, 2022 · Past |
| David Mareska | Vice President, Discovery Chemistry · Since at least Nov 4, 2026 |
| Dylan Hartley | Chief Scientific Officer · Since at least Oct 4, 2024 |
| Gregory J Flesher | President and CEO, Director · Apr 8, 2021 – Dec 9, 2022 · Past |
| James Blake | Senior Vice President of Computational Drug Discovery · Since at least Nov 4, 2026 |
| Jennifer Lam | VP of Finance & Administration · Mar 31, 2022 – Dec 9, 2022 · Past |
| Jim Wong | Vice President, Biological Sciences · Since at least Nov 4, 2026 |
| Kevin S. Litwiler | Senior Vice President of DMPK and Clinical Pharmacology · Since at least Nov 4, 2026 |
| Mark L. Boys | Senior Vice President of Discovery Chemistry · Since at least Nov 4, 2026 |
| Nicholas A. Saccomano | President & Chief Executive Officer · Since at least Oct 4, 2024 |
| Qian Zhao | Vice President and Distinguished Fellow · Since at least Nov 4, 2026 |
| Robbie Alton | Senior Vice President of Clinical Operations · Since at least Nov 4, 2026 |
| Rogan Nunn | General Counsel and Secretary · Since at least Nov 4, 2026 |
| Vineet R Jindal | Chief Financial Officer · Apr 8, 2021 – Dec 10, 2021 · Past |
Log in to ask 6ix AI your own questions about OnKure Therapeutics, Inc.